title: Long-term efficacy of trilostane administered twice daily in dogs with pituitary-dependent hyperadrenocorticism.
abstract: Trilostane is considered an efficacious and safe medication for canine pituitary-dependent hyperadrenocorticism (PDH). Its recommended frequency of administration is once daily. In this prospective study, the efficacy, toxicity, and long-term outcome of trilostane administered twice daily per os were evaluated in 44 dogs with PDH. Mean initial dose was 3.1 mg/kg q 12 hours, and mean final dose was 3.2 mg/kg q 12 hours. The final total daily dose was lower than previously reported for once-daily administration. The mean survival time for affected dogs was 930 days.
authors.affiliation: Veterinary Teaching Hospital, Veterinary School, Complutense University of Madrid, Madrid, Spain.
authors.forename: Dolores Perez
authors.initials: DP
authors.lastname: Alenza
authors.forename: Carolina
authors.initials: C
authors.lastname: Arenas
authors.forename: Mari Luz
authors.initials: ML
authors.lastname: Lopez
authors.forename: Carlos
authors.initials: C
authors.lastname: Melian
mesh_terms: D000308:Adrenocortical Hyperfunction / Q000175:diagnosis / Q000188:drug therapy / Q000401:mortality / Q000662:veterinary*; D000818:Animals; D013196:Dihydrotestosterone / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004283:Dog Diseases / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D004285:Dogs; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D008297:Male; D011446:Prospective Studies; D012449:Safety; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D004791:Enzyme Inhibitors; D013196:Dihydrotestosterone; C009954:trilostane